José Manuel Pérez García

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

Lucia Nogová, Lecia V. Sequist, José Manuel Pérez García et al. · Journal of Clinical Oncology · 2017 · 419 citations

Antitumor Activity, Pathology, Global Phase +17

A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.

Elgene Lim, Komal Jhaveri, José Alejandro Pérez Fidalgo et al. · Journal of Clinical Oncology · 2020 · 56 citations

Phase Ib Study, Breast Oncology, Oncology +14

Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations

David M. Hyman, Ben Tran, Luis Paz‐Ares et al. · JCO Precision Oncology · 2019 · 29 citations · Full text

Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers.

Elena Miranda, Anastasios Stathis, Dagmar Hess et al. · Journal of Clinical Oncology · 2021 · 23 citations

Pathology, Csl-nicd Transcription Complex, Cancer Biology +19

Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.

José Manuel Pérez García, María Gión, Manuel Ruíz‐Borrego et al. · Journal of Clinical Oncology · 2024 · 18 citations · Full text

Breast Oncology, Cancer Management, Immunology +17